Adult participants with low or intermediate-1 risk MDS
No previous treatment with hematopoietic growth factors within 3 months prior to screening
Symptomatic anemia (hemoglobin <10 g/dL) as determined by investigator
Serum erythropoietin <500 milliunits/milliliter (mU/mL) within 14 days prior to the first dose of study treatment
Require no red blood cell transfusion or dependent on <4 units within 8 weeks prior to screening
Clinically stable for at least 1 month prior to entry into the study
For female participants of childbearing potential and male participants with partners of childbearing potential, agreement (by participants and/or partner) to use highly effective form(s) of contraception

NCT02145026_inc_T1
Person
Adult
NCT02145026_inc_T2
Measurement
MDS
NCT02145026_inc_T3
Value
intermediate-1 risk
NCT02145026_inc_T4
Value
low risk
NCT02145026_inc_T5
Scope
low or intermediate-1 risk
NCT02145026_inc_T6
Drug
hematopoietic growth factors
NCT02145026_inc_T7
Temporal
within 3 months prior to screening
NCT02145026_inc_T8
Reference_point
screening
NCT02145026_inc_T9
Condition
anemia
NCT02145026_inc_T10
Qualifier
Symptomatic
NCT02145026_inc_T11
Measurement
hemoglobin
NCT02145026_inc_T12
Value
<10 g/dL
NCT02145026_inc_T13
Measurement
Serum erythropoietin
NCT02145026_inc_T14
Value
<500 milliunits/milliliter
NCT02145026_inc_T15
Temporal
within 14 days prior to the first dose of study treatment
NCT02145026_inc_T16
Procedure
red blood cell transfusion
NCT02145026_inc_T17
Negation
no
NCT02145026_inc_T18
Multiplier
<4 units
NCT02145026_inc_T19
Temporal
within 8 weeks prior to screening
NCT02145026_inc_T20
Condition
stable
NCT02145026_inc_T21
Temporal
for at least 1 month prior to entry into the study
NCT02145026_inc_T22
Reference_point
entry into the study